The presence of racemic mixtures or undesired stereoisomers in chemical synthesis leads to reduced biological activity and potential toxicity. Achieving high optical purity is essential for the efficacy and safety of pharmaceutical intermediates.

Unwanted side products and poor selectivity during halogenation and elimination steps. Achieving high isomeric fidelity ensures efficient synthesis of complex carboxylic acid derivatives.

Contaminants and low yields in fluorinated intermediate synthesis hinder downstream pharmaceutical production. High-purity recovery of volatile reagents like HFIP is necessary to prevent process inefficiency.